Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

Table of Contents

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
Information Sources
Methodology
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Overview

Alzheimer's Disease: Definition and Market Structure
Alzheimer's Disease Pathophysiology

• AD and Amyloid Cascade
• AD and Tauopathy
• AD and Neurotransmitter Systems

Alzheimer's Disease Etiology

• Genetic Factors
• Non-Genetic Factors

Alzheimer's Disease Epidemiology

• Age of Onset
• Incidence, Prevalence and Mortality
• Stages and Severity of AD
• Comorbidities

Diagnosis and Treatment of Alzheimer's

• Diagnosis of Alzheimer's
• Companion Imaging Diagnostics for AS
• CIDX Technologies for Amyloid Visualization
• CIDX Technologies for TAU-NFT Visualization
• Comparative Analysis of Tau Tracers in Development
• CIDX Technologies: Aβ vs. Tau Imaging Technologies
• Concluding Remarks

Pharmaceutical Treatment of AD

Chapter 4 Regulatory Structure

U.S.

• Accelerated Approvals
• Fast Track Designation
• Breakthrough Therapy Designation
• Priority Review
• Controlled Substances Act
• Special Protocol Assessments
• New Surveillance and Safety Requirements

Canada
Mexico
Europe
Asia-Pacific
Rest of the World
Reimbursement Landscape

Chapter 5 Market Dynamics

Market Drivers

• Use of Biomarkers in Diagnosis and Drug Development
• Large Number of Drugs in the Pipeline

Market Restraints

• Patent Expirations of Branded Drugs and Emergence of Generics
• High Failure Rate in Drug Development
• High Cost of Drug Development

Chapter 6 Global Markets for Alzheimer's Disease Therapeutics

Market Overview
Global Market for Alzheimer's Drugs by Mechanism of Action

• Acetylcholinesterase Inhibitors (AChEIs)
• NMDA Drugs

Global Market for Branded/Generic AD Therapeutics by Type
Global Market for AD Therapeutics by Stage of AD

Chapter 7 Market Breakdown by Region

Global Market for Alzheimer's Drugs by Region

• North America
• Europe
• Asia-Pacific
• Rest of the World

Industry Structure

• Impact of Generic AD Therapeutics

Chapter 8 Pipeline Analysis

Overview of the Drug Development Process
Phase III
Phase II
Phase I
Trial Sponsors

Chapter 9 Company Profiles

ABBVIE
ACADIA PHARMACEUTICALS INC.
ALEMBIC PHARMACEUTICALS LTD.
ALEXZA PHARMACEUTICALS
ALKERMES PLC
ALLERGAN PLC
APOTEX INC.
ASTRAZENECA PLC
AUROBINDO PHARMA
AVANIR PHARMACEUTICALS INC.
BOEHRINGER INGELHEIM
BRISTOL-MYERS SQUIBB CO.
BIOGEN
DAIICHI SANKYO CO., LTD.
DR. REDDY'S LABORATORIES LTD.
ELI LILLY AND CO.
EISAI CO., LTD.
F. HOFFMANN-LA ROCHE AG
GLAXOSMITHKLINE PLC
GEDEON RICHTER PLC
IMMUNOCELLULAR THERAPEUTICS LTD.
JOHNSON & JOHNSON
LANNETT CO., INC.
H. LUNDBECK A/S
LUPIN LTD.
MALLINCKRODT
MERCK & CO.
MYLAN NV
NEXTSOURCE BIOTECHNOLOGY LLC
NOVARTIS AG
OTSUKA HOLDINGS CO., LTD.
PFIZER INC.
SANOFI
SUMITOMO DAINIPPON PHARMA CO., LTD.
SUN PHARMACEUTICAL INDUSTRIES LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
TORRENT PHARMACEUTICALS LTD.
UCB SA

Chapter 10 Appendix: Acronyms

 

List of Tables

Summary Table : Global Market for Alzheimer's Drugs, by Region, Through 2025
Table 1 : Alzheimer's Patients and Cost of Care for AD in the U.S., 2015-2030
Table 2 : Pharmacological Treatment of BPSD of Alzheimer's
Table 3 : Computerized Screening Tests Used in Detecting Cognitive Impairment
Table 4 : Brain Imaging Technologies and Application in the Alzheimer's Context
Table 5 : Global Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
Table 6 : Global Market for Alzheimer's AChEIs Drugs, by Region, Through 2025
Table 7 : Global Market for Alzheimer's NMDA Drugs , by Region, Through 2025
Table 8 : Global Market for Alzheimer's Drugs, by Type, Through 2025
Table 9 : Global Market for AD Therapeutics, by Disease Stage, Through 2025
Table 10 : Global Market for Late Stage/Severe AD Therapeutics, by Region, Through 2025
Table 11 : Global Market for Early/Middle Stage AD Therapeutics, by Region, Through 2025
Table 12 : Global Market for Alzheimer's Drugs, by Region, Through 2025
Table 13 : North American Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
Table 14 : North American Market for Alzheimer's Drugs, by Country, Through 2025
Table 15 : North American Market for Alzheimer's Drugs, by Type, Through 2025
Table 16 : European Market for Alzheimer's Drugs, by Country, Through 2025
Table 17 : European Market for Alzheimer's Drugs, by Type, Through 2025
Table 18 : European Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
Table 19 : Asia-Pacific Market for Alzheimer's Drugs, by Type, Through 2025
Table 20 : Asia-Pacific Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
Table 21 : Global Ranking of Leading Players in Alzheimer's Disease Drugs
Table 22 : Agents in Phase III of Alzheimer's Disease Drug Development
Table 23 : Agents in Phase II of Alzheimer's Disease Drug Development
Table 24 : Agents in Phase I of Alzheimer's Disease Drug Development
Table 25 : Trial Sponsor for Each Phase of Alzheimer's Disease Drug Development
Table 26 : Acronyms Used in This Report

List of Figures

Summary Figure : Global Market Shares of Alzheimer's Drugs, by Region, 2019
Figure 1 : Trends in Alzheimer's Patients and Cost of Care for AD in the U.S., 2015-2030
Figure 2 : Pharmaceutical Regulatory Pathways in the U.S. and Europe
Figure 3 : Global Market for Alzheimer's AChEIs Drugs, 2019-2025
Figure 4 : Global Market for Alzheimer's NMDA Drugs, 2019-2025
Figure 5 : Global Market Shares of Alzheimer's Drugs, by Region, 2019
Figure 6 : North American Market for Alzheimer's Drugs, 2019-2025
Figure 7 : European Market for Alzheimer's Drugs, 2019-2025
Figure 8 : Asia-Pacific Market for Alzheimer's Drugs, 2019-2025
Figure 9 : South American Market for Alzheimer's Drugs, 2019-2025
Figure 10 : Middle Eastern and African Market for Alzheimer's Drugs, 2019-2025

当レポートのプレスリリースは発行されておりません。